Sumanta K. Pal, MD, associate professor of the Department of Medical Oncology and Experimental Therapeutics at City of Hope, discusses the data he considers when treating patients with metastatic urothelial carcinoma.
Sumanta K. Pal, MD, associate professor of the Department of Medical Oncology and Experimental Therapeutics at City of Hope, discusses the data he considers when treating patients with metastatic urothelial carcinoma.
While many agents have been approved for this disease, Pal says the decision will rely heavily on the physician’s comfort level with each of the agents when deciding which to use.
In Pal’s opinion, there is the highest amount of evidence with atezolizumab (Tecentriq) and pembrolizumab (Keytruda). When looking at data for atezolizumab from the IMvigor211 trial, many physicians found the results to be negative. However, one particular subset of patients in this study was given atezolizumab in comparison to agents like taxanes.
Brain Cancer Awareness Month: Challenges and Innovations in Treatment
May 13th 2024In an interview with Targeted Oncology for Brain Cancer Awareness Month, Theodore Schwartz, MD, discussed the challenges of targeting brain tumors, emerging therapies, and strategies to overcome the blood-brain barrier.
Read More